Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. develops targeted cancer therapies through a clinical-stage oncology pipeline that includes varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, IM-1021, a ROR1 antibody-drug conjugate, and IM-3050, a FAP-targeted radiotherapy. Company news commonly covers clinical data, regulatory submissions, IND-related progress, oncology conference presentations, and updates on antibody-drug conjugate programs for solid tumors.
Recurring corporate updates also include financial results, business progress reports, investor conference participation, equity compensation actions under the 2024 Inducement Plan, and Nasdaq Listing Rule 5635(c)(4) inducement grants for new employees.
Immunome (Nasdaq: IMNM) announced that its Board Compensation Committee granted inducement stock option awards on June 1, 2026, under the 2024 Inducement Plan.
The awards cover 353,000 shares for twenty new employees at an exercise price of $20.78 per share, vesting over four years per Nasdaq Rule 5635(c)(4).
Immunome (Nasdaq: IMNM) reported detailed Phase 3 RINGSIDE results for varegacestat in adults with progressing desmoid tumors at the 2026 ASCO Meeting.
Varegacestat met the primary and all key secondary endpoints, showing significant benefits in progression-free survival, response rate, pain reduction, tumor volume and supporting an NDA filed with the FDA in April 2026, with an EMA MAA planned by end of 2026.
Immunome (Nasdaq: IMNM) announced that its management will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 10:40 a.m. EDT.
A live audio webcast and 30-day replay will be available via the company’s investor relations website.
Immunome (Nasdaq: IMNM) reported first quarter 2026 results and advanced multiple oncology programs.
The company submitted an NDA for varegacestat in desmoid tumors after Phase 3 RINGSIDE showed an 84% reduction in risk of progression or death (HR=0.16) and 56% vs 9% objective response rate. IM-1021, IM-3050 and IM-1617 progressed in early-stage trials.
Cash and equivalents were $582.7 million, expected to fund operations into 2028. Q1 2026 R&D expenses were $46.4 million, G&A expenses $13.0 million, and net loss was $53.8 million.
Immunome (Nasdaq: IMNM) announced that on May 1, 2026 its Compensation Committee granted inducement non‑statutory stock options to purchase an aggregate of 450,000 shares to nineteen new employees under the 2024 Inducement Plan.
The options have an exercise price of $22.73 per share (closing price on May 1, 2026) and vest over four years: 25% at the one‑year anniversary and the remainder monthly over 36 months, subject to continued service and plan/agreement terms.
Immunome (Nasdaq: IMNM) submitted a New Drug Application to the U.S. FDA for varegacestat to treat adults with desmoid tumors, supported by positive Phase 3 RINGSIDE results.
The trial met its primary endpoint: progression-free survival improved with hazard ratio 0.16 (84% risk reduction; p<0.0001). Confirmed ORR was 56% vs 9% for placebo; most adverse events were grade 1–2.
Immunome (Nasdaq: IMNM) announced that Phase 3 RINGSIDE trial data for varegacestat in progressing desmoid tumors will be presented orally at the 2026 ASCO Annual Meeting in Chicago, May 29–June 2, 2026.
The oral abstract session is scheduled for May 30, 2026, 3:00 PM–6:00 PM CDT, with Mrinal M. Gounder, M.D. as presenter and Abstract 11506. According to the company, the presentation will build on positive topline data reported in December 2025.
Immunome (Nasdaq: IMNM) announced that on April 1, 2026 its Compensation Committee granted inducement non-statutory stock options totaling 188,500 shares to 13 new employees under the 2024 Inducement Plan.
The options carry an exercise price of $22.45 (closing price on April 1, 2026) and vest over four years (25% after one year, then monthly over 36 months), subject to continued service and the plan and option agreement terms.
Immunome (Nasdaq: IMNM) announced that on March 2, 2026 its Compensation Committee granted inducement awards of non-statutory stock options to seven new employees totaling 282,000 shares under the company’s 2024 Inducement Plan in reliance on Nasdaq Listing Rule 5635(c)(4).
Each option has an exercise price of $22.21 (closing price on March 2, 2026) and vests over four years: 25% at the one-year anniversary, then monthly over 36 months, subject to continued service and plan/option-agreement terms.
Immunome (Nasdaq: IMNM) reported full-year 2025 results and a business update. Key clinical and financial highlights include a planned NDA submission for varegacestat in 2Q 2026 after positive Phase 3 RINGSIDE results (PFS hazard ratio 0.16; ORR 56% vs 9%).
Pipeline and corporate items: IM-1021 Phase 1 ongoing with initial 2026 data, three ADC INDs planned in 2026, gross proceeds of $460.5M from a Dec 2025 offering, cash of $653.5M funding operations into 2028, and a 2025 net loss of $212.4M.